"So the SP plunge over one phase 2 trial failure on venous wounds." - yes.
"Theres three or more different types of skin wounds and next test would be ocular wounds. Anyone have details of other trials this company is pursuing ?" - no plans to pursue any other trials yet, as it appears that our treatment has no efficacy benefit at all.
"is that why investors are buying up" - no. Because of high cash levels, although these will be reduced by an unknown amount of costs this quarter and winding down costs etc.
FTT Price at posting:
0.2¢ Sentiment: None Disclosure: Held
